5th Jul 2007 07:00
Stem Cell Sciences plc05 July 2007 For Immediate Release 05 July 2007 Stem Cell Sciences plc Grant of Options Stem Cell Sciences plc, the global biotechnology company focused on thecommercialisation of stem cells and stem cell technologies in research andcell-based therapies, announces that on 19th June 2007 the following Directorsof the Company were granted options over Ordinary Shares in the Company asfollows: - DAVID A DODD, NON-EXECUTIVE CHAIRMAN, has been granted options to acquire250,000 new Ordinary Shares in the Company at a price of 42 pence per share; - JEREMY P SCUDAMORE, NON-EXECUTIVE DIRECTOR, has been granted options toacquire 50,000 new Ordinary Shares in the Company at a price of 42 pence pershare; - LES H WEBB, NON-EXECUTIVE DIRECTOR has been granted options to acquire50,000 new Ordinary Shares in the Company at a price of 42 pence per share.Subsequent to the grant of these options, Les Webb will hold a total of 112,400options over ordinary shares. - HARRY KARELIS, NON-EXECUTIVE DIRECTOR has been granted options to acquire50,000 new Ordinary Shares in the Company at a price of 42 pence per share.Subsequent to the grant of these options, Harry Karelis will hold a total of100,000 options over ordinary shares. The options vest over a four year period and the strike price is based upon theaverage price of the three previous days trading to the grant date of 19th June2007. - Ends - For further information, please contact: Stem Cell Sciences plc (United Kingdom)Sue Furber, Director of Finance and Company Secretary +44 131 662 9829 Notes to EditorsStem Cell Sciences plc (SCS, AIM: STEM, ASX: STC) is a global biotechnologycompany providing the biological infrastructure of cells and cell culture mediato the burgeoning stem cell research market. Stem Cell Sciences' core objective is to develop safe and effective cell-basedtherapies for currently incurable diseases. SCS retains all rights to itstechnology for therapeutic use and is targeting cell-based therapies forneurodegenerative disease and injury. Revenues from Stem Cell Sciences' research business are delivered via anintegrated network of business teams and regional offices in Edinburgh andCambridge (UK), Kobe (Japan), Melbourne (Australia) and San Francisco (USA).This global reach provides the Company with the direct access to markets throughexperienced personnel and local business networks needed to drive SCS businessgrowth in each region. The key challenge for the successful application of stem cells in both researchand clinical applications is the reproducible supply of pure, fullycharacterized stem cells and stem cell-derived specialised cells such as nervesand muscle. This represents a significant technological challenge that willrequire access to multiple technologies and a globally integrated stem cellinitiative. To access cutting edge technologies on a rapid and on-going basis, Stem CellSciences has built an exceptional network of highly interactive collaborationswith academic centres of excellence in the stem cell field. These collaborationshave been the source of our founding technologies and continue to provide anexpanding pipeline of products and intellectual property that are central to theCompany's strategy and success. To facilitate research and technology transfer with its major collaboratingacademic institutions, Stem Cell Sciences' business and scientific teams areusually co-located on site or adjacent to the centre of excellence inindependent company facilities. The Company's key collaborating institutesinclude the Wellcome Trust Centre for Stem Cell Research (University ofCambridge), the Institute of Stem Cell Research (University of Edinburgh), RIKENCentre for Developmental Biology (Kobe) and the Australian Stem Cell Centre(Melbourne). Academic and commercial use of stem cells in basic research and drug discoveryprovides the Company with immediate and growing revenue streams and offsets thecost of technology development for full scale cell production of SCS cell-basedtherapeutics. For further information on the company please visit:www.stemcellsciences.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SThree